Keywords: |
immunohistochemistry; signal transduction; gene mutation; gene sequence; genetics; missense mutation; clinical trial; review; fluorouracil; cancer risk; antineoplastic agent; colorectal cancer; germline; genetic predisposition to disease; chemoprophylaxis; metastasis; gene expression; genetic association; cancer screening; dna methylation; irinotecan; colorectal neoplasms; epigenetics; cpg island; acetylsalicylic acid; celecoxib; cyclooxygenase 2 inhibitor; colorectal adenoma; folinic acid; colon cancer; mismatch repair; microsatellite instability; nonsteroid antiinflammatory agent; colon resection; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; mammalian target of rapamycin inhibitor; oxaliplatin; genetic screening; protein mlh1; lynch syndrome; protein msh2; colorectal neoplasms, hereditary nonpolyposis; cowden syndrome; genetic testing; genetic counseling; hereditary; adenomatous polyp; hormone substitution; hereditary nonpolyposis colorectal cancer; clinical medicine; neoplastic syndromes, hereditary; hereditary colorectal cancer; polyposis; hyperplastic polyposis; ileorectal anastomosis; juvenile polyp; total colon resection; hamartoma syndrome, multiple; peutz-jeghers syndrome
|